|DON'T BUY||$34.280||UNKNOWN||NORTH AMERICAN - LARGE||No|
A generic manufacturer, but do have some branded drugs. The company has been experiencing quite a bit of competition on one of their key branded drugs, so the profit growth is very uncertain, and the share price responded accordingly. There is just not enough clarity going forward.
CEO & Managing Director, GlobeInvest Capital Management